Cure Parkinson’s are proud to publish their latest impact report today. The charity’s achievements range from convening researchers and industry partners to initiating strategic partnerships and from delivering webinars to being the largest not for profit funder of the largest clinical trial for Parkinson’s in the UK; EJS ACT-PD.

At a glance:
  • £8.4 million committed to new research projects.
  • 33 active research projects investigating 36 individual therapeutics with a combined funding commitment of £18.7 million.
  • 17 iLCT dossiers evaluated with 5 compounds prioritised for further clinical testing.
  • 4 webinars and 2 Research Update Meetings for people with Parkinson’s, their families and others interested in Parkinson’s research, reaching a combined total of over 1,000 attendees.
  • 2 new partnerships announced with France Parkinson and Alzheimer’s Research UK.

In this report we evaluate the impact of our research activity, outlining the progress we have made as a charity up to March 2025. The impact of our research activity encompasses our grant funding, our International Linked Clinical Trials (iLCT) programme, our international convening of researchers and collaborators, our involvement of people with Parkinson’s in research, and our outreach about the work we do. Our updated Research Strategy, published in November 2025, provides the focus for our work going forward and we look forward to reporting on the impact arising from that in 2026.

Dr Simon Stott, Director of Research, Cure Parkinson’s

This year Cure Parkinson’s has awarded research funding to 41 institutions across 12 countries, supporting 59 individual principal investigators leading research projects aimed at slowing, stopping, or reversing Parkinson’s. I am also very proud that involving people with Parkinson’s in research is fundamental to everything we do I would like to thank our researchers and generous supporters for making our important work possible.

Helen Matthews, CEO, Cure Parkinson’s

Cure Parkinson’s 2025 Impact Report

This report covers the period 1 April 2024 – 31 March 2025. The next one we produce will be published in summer 2026 and cover the financial year from 1 April 2025 – 31 March 2026.

Read the report
Related content